Fox Run Management, L.L.C. Abb Vie Inc. Transaction History

Fox Run Management, L.L.C.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$154.79 - $180.76 $383,414 - $447,742	2,477 New	2,477 $424,000
Q4 2023 Feb 13, 2024	BUY	$137.6 - $154.97 $340,009 - $382,930	2,471 Added 159.01%	4,025 $623,000
Q3 2023 Nov 07, 2023	SELL	$133.59 - $154.65 $625,334 - $723,916	-4,681 Reduced 75.08%	1,554 $231,000
Q2 2023 Aug 11, 2023	BUY	$132.51 - $164.9 $826,199 - $1.03 Million	6,235 New	6,235 $840,000
Q2 2022 Aug 12, 2022	SELL	$137.62 - $174.96 $294,093 - $373,889	-2,137 Closed	0 $0
Q1 2022 May 10, 2022	BUY	$131.98 - $163.75 $282,041 - $349,933	2,137 New	2,137 $346,000
Q4 2021 Feb 09, 2022	SELL	$107.43 - $135.93 $387,070 - $489,755	-3,603 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$106.4 - $120.78 $151,832 - $172,353	-1,427 Reduced 28.37%	3,603 $389,000
Q2 2019 Jul 17, 2019	BUY	$65.7 - $83.98 $330,471 - $422,419	5,030 New	5,030 $366,000
Q3 2018 Oct 05, 2018	SELL	$88.91 - $98.84 $865,449 - $962,108	-9,734 Closed	0 $0
Q2 2018 Jul 17, 2018	BUY	$89.78 - $106.23 $437,946 - $518,189	4,878 Added 100.45%	9,734 $902,000
Q1 2018 Apr 17, 2018	BUY	$92.01 - $123.21 $446,800 - $598,307	4,856 New	4,856 $460,000

3,817

1.25B

13M

10M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $301B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.